Dianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $40.00 price objective on the stock. HC Wainwright's target price points to a potential upside of 44.14% from the company's current price.

A number of other analysts have also recently commented on the company. Wedbush cut their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research report on Friday, August 9th. Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They issued an "outperform" rating and a $58.00 price objective for the company. Baird R W raised Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. Raymond James lifted their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an "outperform" rating in a report on Friday. Finally, Oppenheimer lifted their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Dianthus Therapeutics presently has an average rating of "Buy" and an average price target of $46.43.

Dianthus Therapeutics Stock Down 4.5 %

DNTH traded down $1.31 on Monday, reaching $27.75. The company's stock had a trading volume of 225,157 shares, compared to its average volume of 193,518. Dianthus Therapeutics has a fifty-two week low of $6.58 and a fifty-two week high of $33.77. The stock has a 50 day moving average of $27.73 and a two-hundred day moving average of $26.60. The company has a market capitalization of $815.02 million, a price-to-earnings ratio of -11.10 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 22.37%. The company had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. As a group, analysts anticipate that Dianthus Therapeutics will post -2.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC acquired a new position in shares of Dianthus Therapeutics during the first quarter worth about $89,761,000. RA Capital Management L.P. acquired a new position in Dianthus Therapeutics during the first quarter worth about $69,990,000. Great Point Partners LLC grew its position in Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock worth $19,615,000 after buying an additional 132,929 shares during the period. Vanguard Group Inc. grew its position in Dianthus Therapeutics by 250.0% during the first quarter. Vanguard Group Inc. now owns 537,828 shares of the company's stock worth $16,135,000 after buying an additional 384,182 shares during the period. Finally, Janus Henderson Group PLC acquired a new position in Dianthus Therapeutics during the first quarter worth about $11,251,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.